Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

Lung cancer and melanoma funders form first-ever research collaboration

LUNGevity Foundation today announced a partnership with the Lung Cancer Research Foundation and Melanoma Research Alliance to co-fund new innovative research on PD-1 inhibitor treatment options for both non-small cell lung cancer (NSCLC) and metastatic melanoma (MM) patients with brain metastases.

9 Jul 2014

$FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL$

FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

Novartis announced today that the United States Food and Drug Administration has granted Breakthrough Therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL).

7 Jul 2014

Lung cancer patients could benefit from new 'QTA' technique

Lung cancer patients could receive more precise treatment, and their progress could be better tracked, using a new high-tech method of non-invasive medical imaging analysis, according to a study published today by the journal PLOS ONE.

3 Jul 2014

Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

Helsinn Group, the company focused on building quality cancer care, today announces that rights to anamorelin, its innovative ghrelin receptor agonist, have been granted in Turkey to GEN Ilaç.

30 Jun 2014

Surgical biopsies can be safely performed on selected patients with late-stage lung cancer

Researchers at UC Davis have determined that surgical biopsies can be safely performed on select patients with late-stage non-small cell lung cancer, which should enhance their access to drugs that target specific genetic mutations such as epidermal growth factor receptor (EGFR).

27 Jun 2014

EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, today announced plans to move forward with a Phase 2a clinical trial in the U.S. using its formulation of EGFR-targeted, EDV nanocells packaged with doxorubicin for the treatment of recurrent glioblastoma (GBM), a common and aggressive type of brain tumor.

26 Jun 2014

Intercalated erlotinib–eribulin ‘feasible’ without added efficacy

Erlotinib can be intercalated with the anti-tubule agent eribulin mesylate for patients with advanced non-small-cell lung cancer but it is unlikely to increase treatment efficacy in those without epidermal growth factor receptor activating mutations, research suggests.

25 Jun 2014

New study explores effects of immunotherapy, chemotherapy drugs on non-small cell lung cancer

A new study offered at Houston Methodist Hospital will compare an emerging immunotherapy drug to an existing chemotherapy drug and look at the effects both drugs have on the development of non-small cell lung cancer, a type of cancer which makes up about 85 percent of lung cancer cases.

24 Jun 2014

Third-line treatment options remain elusive for advanced, EGFR wild-type NSCLC

Phase II study findings show only marginal positive effects of third-line treatment with afatinib for advanced non-small-cell lung cancer in patients with wild-type epidermal growth-factor receptor tumour status.

23 Jun 2014

Clovis Oncology begins TIGER2 study for treatment of NSCLC patients with EGFR/T790M mutations

Clovis Oncology, Inc. announced today that the TIGER2 study has commenced with the dosing of the first patient at a U.S. study site.

23 Jun 2014

Six-gene signature predicts survival after targeted therapy for NSCLC

The presence of a six-gene profile in the microRNA of patients with advanced non-squamous non-small-cell lung cancer predicts reduced survival likelihood after first-line treatment with targeted therapy followed by chemotherapy for disease progression, indicate research results.

20 Jun 2014

FGFR1 amplification predicts poor outcome in early-stage NSCLC

Amplification of fibroblast growth factor receptor 1 is associated with poor clinical outcome in patients with early-stage non-small-cell lung cancer, Swiss researchers report.

20 Jun 2014

SCLC tumours replicated in mice from patients' CTCs

Scientists have used circulating tumour cells taken from patients with small-cell lung cancer to grow explant tumours in mice that retain the original’s morphological and genetic characteristics.

20 Jun 2014

Clinically relevant mouse model for difficult-to-treat squamous cell lung cancer

Only 15% of patients with squamous cell lung cancer - the second most common lung cancer - survive five years past diagnosis.

20 Jun 2014

BIND Therapeutics inks research agreement with Roche to discover novel nanomedicines

BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins, today announced that it has entered into a research agreement with Roche to discover novel nanomedicines using Accurins for the treatment of diseases in therapeutic areas outside of oncology.

19 Jun 2014

Protein test predicts NSCLC survival benefit for chemotherapy over erlotinib

Italian study results confirm that a multivariate serum protein test predicts improved survival after treatment with chemotherapy versus erlotinib for non-small-cell lung cancer, but only among patients who are likely to have a poor outcome with the latter treatment type.

16 Jun 2014

Survival differences after docetaxel, erlotinib are EGFR dependent

Results from the DELTA trial indicate no significant differences in progression-free or overall survival after treatment with docetaxel versus erlotinib in non-small-cell lung cancer patients unselected for their epidermal growth factor receptor mutation status.

16 Jun 2014

Adjuvant chemotherapy and adjuvant radiation recommended for R1 resected cancer patients

A landmark survey of more than 700 specialists provides crucial real-world insight into the treatments most oncologists choose for lung cancer patients whose tumour has been incompletely resected, an expert from the European Society for Medical Oncology (ESMO) says.

11 Jun 2014

Mirna enrolls first patient in hematological malignancy cohort of MRX34 Phase 1 clinical trial

Mirna Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering microRNA-based Replacement Therapy to treat cancer, today announced the enrollment of the first patient in the hematological malignancy cohort of its ongoing Phase 1 clinical trial of MRX34, the company's lead product candidate and first microRNA mimic in human clinical trials in oncology.

11 Jun 2014

Immune Design begins treatment in LV305 Phase 1 clinical trial for cancer

Immune Design, a clinical-stage immunotherapy company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced treatment of the first patient in a Phase 1 clinical trial of LV305, an immuno-oncology investigational agent from the company's DCVexTM lentiviral vector platform.

5 Jun 2014

Small Cell Lung Cancer News and Research

Lung cancer and melanoma funders form first-ever research collaboration

FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

Lung cancer patients could benefit from new 'QTA' technique

Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

Surgical biopsies can be safely performed on selected patients with late-stage lung cancer

EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

Intercalated erlotinib–eribulin ‘feasible’ without added efficacy

New study explores effects of immunotherapy, chemotherapy drugs on non-small cell lung cancer

Third-line treatment options remain elusive for advanced, EGFR wild-type NSCLC

Clovis Oncology begins TIGER2 study for treatment of NSCLC patients with EGFR/T790M mutations

Six-gene signature predicts survival after targeted therapy for NSCLC

FGFR1 amplification predicts poor outcome in early-stage NSCLC

SCLC tumours replicated in mice from patients' CTCs

Clinically relevant mouse model for difficult-to-treat squamous cell lung cancer

BIND Therapeutics inks research agreement with Roche to discover novel nanomedicines

Protein test predicts NSCLC survival benefit for chemotherapy over erlotinib

Survival differences after docetaxel, erlotinib are EGFR dependent

Adjuvant chemotherapy and adjuvant radiation recommended for R1 resected cancer patients

Mirna enrolls first patient in hematological malignancy cohort of MRX34 Phase 1 clinical trial

Immune Design begins treatment in LV305 Phase 1 clinical trial for cancer

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News